Core Viewpoint - The company,沃特股份, announced the approval of a cash management plan using idle funds, indicating a strategic move to optimize financial resources [1] Group 1: Cash Management Plan - The company plans to use up to RMB 250 million (including RMB 250 million, which can be recycled) of temporarily idle raised funds for cash management [1] - Additionally, the company intends to utilize up to RMB 200 million (including RMB 200 million, which can be recycled) of its own funds for the same purpose [1] - The authorization for cash management is valid for 12 months from the date of the board's approval [1] Group 2: Governance and Oversight - The cash management plan was approved during the fifth board meeting and the eighth supervisory meeting [1] - The management team is authorized to finalize and sign relevant implementation agreements or contracts [1] - The financial management center of the company will handle the related matters [1]

Core Viewpoint - The company announced the approval of a proposal to utilize part of its idle self-owned funds for cash management, with a total limit of up to 800 million RMB [1] Group 1 - The sixth board meeting is scheduled for August 21, 2025, where the cash management proposal will be reviewed [1] - The company and its subsidiaries will invest in high-security, high-liquidity, and low-risk financial products [1] - The usage period for the funds is valid for 12 months from the date of shareholder meeting approval, allowing for rolling use within the limit [1]

Group 1 - The company announced the approval of a proposal to use part of its temporarily idle raised funds for cash management [1] - The approved amount for cash management is up to 200 million RMB, which will be invested in safe and liquid principal-protected investment products [1] - The cash management activities can be conducted from the date of board approval until November 30, 2025, without affecting the construction of investment projects and normal operations [1]

Core Viewpoint - The board of directors of Dongguan Kaige Precision Machinery Co., Ltd. has approved the 2025 semi-annual report and related documents, confirming their compliance with legal and regulatory requirements, and asserting the accuracy and completeness of the information presented [1][2]. Group 1: Board Meeting Resolutions - The board meeting held on August 21, 2025, was legally convened with all five directors present, and the resolutions passed were deemed valid [1]. - The 2025 semi-annual report and its summary were approved, reflecting the company's actual situation without any false statements or omissions [1][2]. - The special report on the use of raised funds for the first half of 2025 was also approved, confirming compliance with relevant regulations and the absence of any misuse of funds [2]. Group 2: Financial Management Decisions - The board approved the use of up to RMB 400 million of idle raised funds for cash management, allowing investment in high-security and liquid financial products, with a validity period of 12 months [3]. - The board's decision to recognize asset impairment provisions was based on sufficient evidence and compliance with accounting standards, accurately reflecting the company's financial status [3]. - The board approved the use of self-owned assets as collateral for bank credit applications to meet operational funding needs, ensuring no significant financial risk to the company [4]. Group 3: Upcoming Shareholder Meeting - The board has scheduled the first extraordinary general meeting of 2025 for September 9, 2025, to discuss the collateralization proposal, combining on-site and online voting methods [5].

Core Points - The company held its 16th meeting of the second supervisory board on August 21, 2025, where all three supervisors attended, confirming the meeting's legality and effectiveness [1] - The supervisory board unanimously agreed that the procedures for preparing and reviewing the 2025 semi-annual report complied with relevant laws and regulations, and the report accurately reflects the company's actual situation [1][2] - The board confirmed that the management and use of raised funds complied with regulatory requirements, with no violations noted [2] - The supervisory board approved the use of idle raised funds for cash management, which is expected to enhance fund utilization efficiency and generate investment returns [2][3] - The board agreed that the provision for asset impairment was in line with accounting standards and accurately reflects the company's financial status [3] - The decision to use self-owned assets as collateral for bank credit applications was deemed beneficial for the company's development and compliant with relevant regulations [3] - The proposals will be submitted for review at the company's first extraordinary general meeting of 2025 [4]

Core Viewpoint - Chengdu Gas announced the approval of a cash management plan allowing the use of up to RMB 1 billion of its own funds annually for cash management purposes, excluding time deposits and large certificates of deposit, with a validity period of 36 months from the date of approval [1] Group 1 - The third meeting of the third board of directors and the eighth meeting of the third supervisory board will be held on August 22, 2025 [1] - The cash management plan does not require shareholder approval as it falls within the board's approval authority [1] - The authorization for cash management is effective for 36 months from the date of the board's approval [1]

Key Points - The report details the fundraising and usage of funds by Shanghai Aopumai Biotechnology Co., Ltd. for the first half of 2025, ensuring compliance with relevant regulations [1][2] - The total amount raised from the initial public offering (IPO) was approximately RMB 1.644 billion, with a net amount of RMB 1.637 billion after deducting issuance costs [1] - As of June 30, 2025, the company had spent RMB 318.4048 million on fundraising projects and had a remaining balance of RMB 151.2954 million in the fundraising account [1][2] Fundraising Overview - The actual amount raised was RMB 1,643,705,576.40, with a net amount of RMB 1,637,000,000 after fees [1] - The company utilized RMB 318.4048 million for project expenditures and invested RMB 546 million in financial products [1] - The company generated a net interest income of RMB 48.6477 million from the funds [1] Fund Usage and Management - The company has established a dedicated account for fundraising, with a balance of RMB 151.2954 million as of June 30, 2025 [1][2] - The company has permanently supplemented working capital with surplus funds amounting to RMB 192.8819 million [1] - The company has implemented a cash management strategy for idle funds, allowing for investment in high-security, liquid financial products [2][3] Project Status - The company has completed the fundraising projects "Aopumai CDMO Biopharmaceutical Commercialization Production Platform" and "Aopumai Cell Culture R&D Center," with surplus funds permanently allocated to working capital [1][2] - There were no changes to the fundraising project usage during the reporting period [4] Compliance and Reporting - The company has adhered to the regulations regarding fundraising management and disclosure, ensuring timely and accurate reporting of fundraising activities [4] - There were no violations in the management and disclosure of fundraising [4]

Summary of Key Points Core Viewpoint The company intends to utilize part of its temporarily idle raised funds for cash management to enhance fund efficiency and maximize shareholder returns while ensuring compliance with regulations and maintaining the intended use of the raised funds [1][7]. Group 1: Fundraising and Management - The company raised a total of RMB 1,643,705,576.40 through its initial public offering, with a net amount after expenses being RMB 1,643,705,576.40 [1][2]. - All raised funds are managed in a dedicated account, with agreements in place between the company, its subsidiaries, and the commercial banks [2]. Group 2: Cash Management Plan - The company plans to use up to RMB 70,000.00 million of temporarily idle raised funds for cash management, with a rolling usage period of 12 months [3][4]. - The investment products will include safe and liquid options such as fixed deposits and structured deposits, ensuring that these funds are not used for pledging or securities investment [4]. Group 3: Approval and Oversight - The board of directors and the supervisory board have approved the cash management plan, confirming that it will not affect the normal operation of the fundraising projects [5][6]. - The supervisory board supports the plan, stating it will not harm the interests of the company or its shareholders [6]. Group 4: Compliance and Risk Management - The cash management activities are in compliance with relevant regulations and internal management systems, ensuring no change in the intended use of the raised funds [7]. - The company will implement strict risk control measures, focusing on high-security and high-liquidity investment products, while monitoring market conditions [5].

Core Points - The company held the 26th meeting of the 7th Board of Directors, where several key resolutions were passed regarding the election of the 8th Board of Directors and changes to company governance [1][2][3] Group 1: Board Elections - The company approved the election of non-independent directors for the 8th Board, nominating five candidates including Wang Dongying and Zeng Yangyun, with a term of three years [1][2] - The election of independent directors was also approved, nominating three candidates including Zheng Guojian, with the same three-year term [2][3] Group 2: Governance Changes - The company decided to eliminate the supervisory board and transfer its responsibilities to the audit committee of the Board of Directors, aiming to streamline management processes [4][5] - Amendments to the company's articles of association were approved, which will take effect after shareholder approval [4][5] Group 3: Financial Management - The company plans to use up to 2 billion RMB of idle funds for cash management, investing in low-risk financial products [11] - The company approved a report on the use of raised funds, ensuring compliance with legal requirements [9][10] Group 4: Upcoming Meetings - A second extraordinary general meeting is scheduled for September 12, 2025, to review the resolutions passed in the recent board meeting [12]

华源证券股份有限公司 关于国安达股份有限公司 使用部分暂时闲置自有资金进行现金管理的核查意见 华源证券股份有限公司（以下简称"华源证券"或"保荐机构"）作为国安 达股份有限公司（以下简称"国安达"或"公司"）持续督导的保荐机构，根据 《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司自律监管指引第 上市公司自律监管指引第 2 号—创业板上市公司规范运作》等相关规定，就公司 使用部分暂时闲置自有资金进行现金管理事项进行了核查，并出具核查意见如下： 一、本次拟使用部分暂时闲置自有资金进行现金管理的情况 在保障公司正常经营资金周转需要、有效控制投资风险的情况下，合理利用 部分暂时闲置自有资金进行现金管理，可以提高资金使用效率，增加公司自有资 金收益，为公司和股东获得更多的投资回报。 公司拟使用额度不超过人民币 20,000 万元（含本数）的暂时闲置自有资金 进行现金管理，使用期限自公司 2025 年第三次临时股东会审议通过之日起 12 个月内有效（前次经 2024 年第三次临时股东大会审议通过的使用部分暂时闲置 自有资金 50,000 万元进行现金管理的额度，将于 2025 年 9 月 12 日到期）。在 上 ...